KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Deffered Revenue: 2010-2020

Historic Non-Current Deffered Revenue for Nektar Therapeutics (NKTR) over the last 11 years, with Dec 2020 value amounting to $2.5 million.

  • Nektar Therapeutics' Non-Current Deffered Revenue fell 3.52% to $2.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $2.5 million, marking a year-over-year decrease of 3.52%. This contributed to the annual value of $2.5 million for FY2020, which is 3.52% down from last year.
  • Nektar Therapeutics' Non-Current Deffered Revenue amounted to $2.5 million in FY2020, which was down 3.52% from $2.6 million recorded in FY2019.
  • In the past 5 years, Nektar Therapeutics' Non-Current Deffered Revenue registered a high of $51.9 million during FY2016, and its lowest value of $2.5 million during FY2020.
  • Its 3-year average for Non-Current Deffered Revenue is $5.3 million, with a median of $2.6 million in 2019.
  • Data for Nektar Therapeutics' Non-Current Deffered Revenue shows a maximum YoY plummeted of 76.23% (in 2019) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $51.9 million in 2016, then crashed by 63.34% to $19.0 million in 2017, then plummeted by 43.52% to $10.7 million in 2018, then plummeted by 76.23% to $2.6 million in 2019, then decreased by 3.52% to $2.5 million in 2020.